NCT04729959: An ongoing trial by National Cancer Institute (NCI)
This trial is ongoing. It must report results 1 day, 8 hours ago.
Full data
| Full entry on ClinicalTrials.gov | NCT04729959 |
|---|---|
| Title | A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 11, 2022 |
| Completion date | June 15, 2025 |
| Required reporting date | June 15, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 15, 2026 |
| Days late | None |